☆ 4.7 Review

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials

FRONTIERS IN ENDOCRINOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Endocrinology & Metabolism

Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis

Ke He et al.

DIABETES OBESITY & METABOLISM (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial

Domenica M. Rubino et al.

Summary: In overweight or obese adults without diabetes, once-weekly subcutaneous semaglutide resulted in significantly greater weight loss compared to once-daily subcutaneous liraglutide when added to counseling for diet and physical activity over 68 weeks.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Qingyang Shi et al.

Summary: This study summarised the latest evidence on the benefits and harms of weight-lowering drugs. The findings suggest that the combination of phentermine-topiramate and GLP-1 receptor agonists is the most effective, with semaglutide potentially being the most effective GLP-1 receptor agonist.

LANCET (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Takashi Kadowaki et al.

Summary: Semaglutide was found to be effective in weight management in obese individuals from east Asia, leading to significant reductions in bodyweight and abdominal visceral fat area. It represents a promising treatment option for weight management in this population.

LANCET DIABETES & ENDOCRINOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Obesity on In-Hospital Outcomes in Veno-Arterial ECMO Patients

Ilija Djordjevic et al.

Summary: A study on weight-associated differences of patients treated with VA ECMO revealed that obese class II patients had the highest risk of death, and obese patients showed a trend towards higher in-hospital mortality compared to non-obese patients.

HEART LUNG AND CIRCULATION (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis

Ping Zhong et al.

Summary: This meta-analysis examined the effectiveness and safety of once-weekly semaglutide in treating overweight or obese adults. The results showed that once-weekly semaglutide was superior to placebo in terms of weight loss, achievement of weight reduction targets, cardiometabolic risk reduction, and improvement in health-related quality of life.

ENDOCRINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

Anne Flint et al.

Summary: In patients with NAFLD, the change in liver stiffness between semaglutide and placebo was not significantly different, but semaglutide significantly reduced liver fat content compared to placebo. Additionally, semaglutide also led to decreases in liver enzymes, body weight, and HbA(1c) levels.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

Martin Friedrichsen et al.

Summary: This study investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity. The results showed that semaglutide significantly suppressed appetite, improved control of eating, and reduced food cravings, ad libitum energy intake, and body weight compared to placebo. However, there was no evidence of delayed gastric emptying with semaglutide at week 20.

DIABETES OBESITY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?

Young Jin Tak et al.

Summary: The guidelines for obesity control recommend lifestyle interventions along with medical treatment for overweight patients to achieve significant weight loss and improved cardiometabolism. Recent studies have shown that a combination of pharmacotherapy and behavior-based interventions can lead to effective weight reduction, although careful consideration of benefits and risks is necessary when initiating drug therapy in obese individuals.

CURRENT OBESITY REPORTS (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial

Thomas A. Wadden et al.

Summary: This study compared the effects of once-weekly subcutaneous semaglutide with placebo as an adjunct to intensive behavioral therapy and initial low-calorie diet for weight management in adults with overweight or obesity. The results showed that semaglutide led to significantly greater weight loss compared to placebo over 68 weeks, with a higher proportion of participants achieving weight loss goals. More research is needed to evaluate the long-term effectiveness of this treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies et al.

Summary: In this study, once-weekly subcutaneous semaglutide 2.4 mg was shown to achieve a significantly greater and clinically meaningful weight reduction compared to placebo in adults with overweight or obesity and type 2 diabetes. Adverse events, particularly gastrointestinal events, were more common with semaglutide compared to placebo.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Obesity: Overview of Weight Management

Meetal Mehta et al.

Summary: This article reviews the multifaceted personalized treatment approach for obesity, including lifestyle interventions, pharmacotherapy, endoscopic procedures, and surgical procedures. However, current literature lacks large studies on the safety and efficacy of combination therapies involving pharmacotherapy plus surgical procedures.

ENDOCRINE PRACTICE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study

Mojca Jensterle et al.

Summary: The study evaluated the effect of semaglutide on tongue fat storage in obese women with PCOS. Results showed that semaglutide significantly reduced tongue fat tissue and fat proportion, which was associated with reductions in body weight, BMI, and waist circumference. Further studies are needed to assess the clinical importance of these findings.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Obesity: Epidemiology, Pathophysiology, and Therapeutics

Xihua Lin et al.

Summary: Obesity is a complex multifactorial disease with negative health effects, mainly caused by an energy imbalance. Treatment strategies should focus on biological mechanisms and reducing BMI.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis

Kia Vosoughi et al.

Summary: This study conducted a systematic review and network meta-analysis to assess the weight loss effects of 7 GLP-1 agents in obesity. Results showed varying degrees of weight loss with different drugs, with semaglutide agents demonstrating the most significant effects.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

Robert F. Kushner et al.

OBESITY (2020)

添加到收藏夹

Article Medicine, General & Internal

Obesity in adults: a clinical practice guideline

Sean Wharton et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Gilles R. Dagenais et al.

CARDIOVASCULAR DIABETOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines

Thomas Semlitsch et al.

OBESITY REVIEWS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Soren L. Kristensen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Pharmacotherapy of obesity: Available medications and drugs under investigation

Eleni Pilitsi et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2019)

添加到收藏夹

Article Medicine, Research & Experimental

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Ippei Ikushima et al.

ADVANCES IN THERAPY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Ildiko Lingvay et al.

DIABETES CARE (2018)

添加到收藏夹

Article Medicine, General & Internal

Maintenance of Lost Weight and Long-Term Management of Obesity

Kevin D. Hall et al.

MEDICAL CLINICS OF NORTH AMERICA (2018)

添加到收藏夹

Review Endocrinology & Metabolism

Glucagon-like peptide 1 in health and disease

Andreas Andersen et al.

NATURE REVIEWS ENDOCRINOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O'Neil et al.

LANCET (2018)

添加到收藏夹

Review Endocrinology & Metabolism

Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research

Philip A. Levin et al.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

John Blundell et al.

DIABETES OBESITY & METABOLISM (2017)

添加到收藏夹

Article Public, Environmental & Occupational Health

Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe

Mika Kivimaki et al.

LANCET PUBLIC HEALTH (2017)

添加到收藏夹

Article Endocrinology & Metabolism

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

W. Timothy Garvey et al.

ENDOCRINE PRACTICE (2016)

添加到收藏夹

Article Medicine, General & Internal

Weight loss intervention adherence and factors promoting adherence: a meta-analysis

Mark Lemstra et al.

PATIENT PREFERENCE AND ADHERENCE (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium

Rudolph L. Leibel et al.

DIABETES (2015)

添加到收藏夹

Article Endocrinology & Metabolism

European Guidelines for Obesity Management in Adults

Volkan Yumuk et al.

OBESITY FACTS (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect

Stephanie Sisley et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Review Endocrinology & Metabolism

Impact of Weight Regain on Metabolic Disease Risk: A Review of Human Trials

Cynthia M. Kroeger et al.

JOURNAL OF OBESITY (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice

Benjamin J. Lamont et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

添加到收藏夹

Review Physiology

Biology's response to dieting: the impetus for weight regain

Paul S. MacLean et al.

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)

添加到收藏夹

Article Nutrition & Dietetics

Economic Contextual Factors, Food Consumption, and Obesity among US Adolescents

Lisa M. Powell et al.

JOURNAL OF NUTRITION (2010)

添加到收藏夹

Article Genetics & Heredity

Genome-Wide Association Scan Meta-Analysis Identifies Three Loci Influencing Adiposity and Fat Distribution

Cecilia M. Lindgren et al.

PLOS GENETICS (2009)

添加到收藏夹

Review Gastroenterology & Hepatology

Biology of incretins: GLP-1 and GIP

Laurie L. Baggio et al.

GASTROENTEROLOGY (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.